HRP20210299T1 - Inhibitori histonske demetilaze - Google Patents
Inhibitori histonske demetilaze Download PDFInfo
- Publication number
- HRP20210299T1 HRP20210299T1 HRP20210299TT HRP20210299T HRP20210299T1 HR P20210299 T1 HRP20210299 T1 HR P20210299T1 HR P20210299T T HRP20210299T T HR P20210299TT HR P20210299 T HRP20210299 T HR P20210299T HR P20210299 T1 HRP20210299 T1 HR P20210299T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- aryl
- alkyl
- heteroaryl
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017201P | 2014-06-25 | 2014-06-25 | |
| PCT/US2015/037812 WO2015200709A1 (en) | 2014-06-25 | 2015-06-25 | Histone demethylase inhibitors |
| EP15811523.8A EP3160952B1 (en) | 2014-06-25 | 2015-06-25 | Histone demethylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210299T1 true HRP20210299T1 (hr) | 2021-04-16 |
Family
ID=54929774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210299TT HRP20210299T1 (hr) | 2014-06-25 | 2015-06-25 | Inhibitori histonske demetilaze |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US10385047B2 (https=) |
| EP (3) | EP3741749A1 (https=) |
| JP (1) | JP6521535B2 (https=) |
| KR (1) | KR102591897B1 (https=) |
| CN (2) | CN106660982B (https=) |
| AR (1) | AR100997A1 (https=) |
| AU (1) | AU2015279719B2 (https=) |
| BR (1) | BR112016030367A2 (https=) |
| CA (1) | CA2953437C (https=) |
| CL (1) | CL2016003301A1 (https=) |
| CO (1) | CO2017000359A2 (https=) |
| CY (1) | CY1123906T1 (https=) |
| DK (1) | DK3160952T3 (https=) |
| EA (1) | EA031200B1 (https=) |
| EC (1) | ECSP17004931A (https=) |
| ES (1) | ES2862648T3 (https=) |
| HR (1) | HRP20210299T1 (https=) |
| HU (1) | HUE053876T2 (https=) |
| IL (1) | IL249629A0 (https=) |
| LT (1) | LT3160952T (https=) |
| MX (1) | MX375219B (https=) |
| NZ (1) | NZ728120A (https=) |
| PL (1) | PL3160952T3 (https=) |
| PT (1) | PT3160952T (https=) |
| SA (1) | SA516380585B1 (https=) |
| SG (1) | SG11201610813TA (https=) |
| SI (1) | SI3160952T1 (https=) |
| TW (2) | TWI715533B (https=) |
| WO (1) | WO2015200709A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015014968A2 (pt) | 2012-12-21 | 2017-07-11 | Quanticel Pharmaceuticals Inc | inibidores de histona-desmetilase |
| SI3160952T1 (sl) | 2014-06-25 | 2021-07-30 | Celgene Quanticel Research, Inc. | Zaviralci histon demetilaz |
| ES2910226T3 (es) | 2014-09-17 | 2022-05-12 | Celgene Quanticel Res Inc | Inhibidores de desmetilasa de histonas |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2017117154A1 (en) * | 2015-12-28 | 2017-07-06 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3430008B1 (en) * | 2016-03-15 | 2022-05-18 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3600301B1 (en) * | 2017-03-30 | 2024-07-03 | Albert-Ludwigs-Universität Freiburg | Kdm4 inhibitors |
| CN109825551B (zh) * | 2019-02-21 | 2022-08-02 | 深圳大学 | 一种评价组蛋白赖氨酸去甲基转移酶活性的方法 |
| CN111679072B (zh) * | 2020-06-15 | 2022-04-29 | 温州医科大学 | Kdm6b蛋白在乳腺癌预后评估试剂盒、诊断试剂盒中的应用 |
| JP2024518712A (ja) * | 2021-04-09 | 2024-05-02 | タキオン セラピューティクス，インコーポレーテッド | Ｋｄｍ４阻害剤による癌の処置 |
| WO2023023112A1 (en) * | 2021-08-18 | 2023-02-23 | Celgene Corporation | Process for preparing histone demethylase inhibitors |
| EP4452249A4 (en) * | 2021-12-23 | 2026-03-11 | Tachyon Therapeutics Inc | PHARMACEUTICAL FORMULATIONS COMPRISING 3-({[(4R)-7-{METHYL[4-(PROPAN-2-YL)PHENYL]AMINO}-3,4-DIHYDRO-2H-L-BENZOPYRAN-4-YL]METHYL}AMINO)PYRIDINE-4-CARBOXYLIC ACID |
| TW202412816A (zh) | 2022-06-10 | 2024-04-01 | 美商弗沃德醫療公司 | ＴＮＦ—α活性調節劑 |
| WO2023250480A1 (en) * | 2022-06-23 | 2023-12-28 | The Cleveland Clinic Foundation | 3-βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF |
| KR20250067936A (ko) * | 2022-09-21 | 2025-05-15 | 셀진 코포레이션 | 3-(｛[(4r)-7-｛메틸[4-(프로판-2-일)페닐]아미노｝-3,4-디하이드로-2h-1-벤조피란-4-일]메틸｝아미노)피리딘-4-카르복실산l-라이신 염의 결정형, 히스톤 탈메틸화효소 억제제 |
| CN115974647B (zh) * | 2022-12-05 | 2024-09-03 | 江苏宏邦化工科技有限公司 | 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法 |
| WO2025085527A1 (en) * | 2023-10-16 | 2025-04-24 | The Cleveland Clinic Foundation | 3βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101851173A (zh) * | 2001-09-14 | 2010-10-06 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| DE102004039876A1 (de) | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| CN101466670B (zh) * | 2006-04-07 | 2013-04-17 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| US7898712B2 (en) | 2008-06-27 | 2011-03-01 | Lockheed Martin Corporation | Risley integrated steering module |
| GB201112607D0 (en) | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| CA2834548C (en) * | 2011-04-28 | 2021-06-01 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| WO2013143597A1 (en) * | 2012-03-29 | 2013-10-03 | Glaxo Group Limited | Demethylase enzymes inhibitors |
| WO2014089368A1 (en) | 2012-12-05 | 2014-06-12 | Bio-Rad Laboratories, Inc | Methods for polymerase chain reaction copy number variation assays |
| CA2894399A1 (en) * | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| SMT201800070T1 (it) | 2012-12-19 | 2018-03-08 | Celgene Quanticel Res Inc | Inibiorti di istone demetilasi |
| BR112015014968A2 (pt) | 2012-12-21 | 2017-07-11 | Quanticel Pharmaceuticals Inc | inibidores de histona-desmetilase |
| SI3160952T1 (sl) | 2014-06-25 | 2021-07-30 | Celgene Quanticel Research, Inc. | Zaviralci histon demetilaz |
| EP3600301B1 (en) * | 2017-03-30 | 2024-07-03 | Albert-Ludwigs-Universität Freiburg | Kdm4 inhibitors |
-
2015
- 2015-06-25 SI SI201531524T patent/SI3160952T1/sl unknown
- 2015-06-25 EP EP20184106.1A patent/EP3741749A1/en active Pending
- 2015-06-25 TW TW104120633A patent/TWI715533B/zh active
- 2015-06-25 PL PL15811523T patent/PL3160952T3/pl unknown
- 2015-06-25 PT PT158115238T patent/PT3160952T/pt unknown
- 2015-06-25 KR KR1020177002223A patent/KR102591897B1/ko active Active
- 2015-06-25 EA EA201692483A patent/EA031200B1/ru unknown
- 2015-06-25 LT LTEP15811523.8T patent/LT3160952T/lt unknown
- 2015-06-25 AU AU2015279719A patent/AU2015279719B2/en active Active
- 2015-06-25 US US15/321,702 patent/US10385047B2/en active Active
- 2015-06-25 NZ NZ728120A patent/NZ728120A/en unknown
- 2015-06-25 CN CN201580045921.2A patent/CN106660982B/zh active Active
- 2015-06-25 BR BR112016030367A patent/BR112016030367A2/pt not_active Application Discontinuation
- 2015-06-25 WO PCT/US2015/037812 patent/WO2015200709A1/en not_active Ceased
- 2015-06-25 JP JP2016574454A patent/JP6521535B2/ja active Active
- 2015-06-25 HR HRP20210299TT patent/HRP20210299T1/hr unknown
- 2015-06-25 MX MX2016017407A patent/MX375219B/es active IP Right Grant
- 2015-06-25 EP EP20184107.9A patent/EP3738960A1/en not_active Withdrawn
- 2015-06-25 TW TW109143458A patent/TWI758004B/zh active
- 2015-06-25 CN CN202010813617.0A patent/CN111909083B/zh active Active
- 2015-06-25 HU HUE15811523A patent/HUE053876T2/hu unknown
- 2015-06-25 EP EP15811523.8A patent/EP3160952B1/en active Active
- 2015-06-25 CA CA2953437A patent/CA2953437C/en active Active
- 2015-06-25 ES ES15811523T patent/ES2862648T3/es active Active
- 2015-06-25 DK DK15811523.8T patent/DK3160952T3/da active
- 2015-06-25 SG SG11201610813TA patent/SG11201610813TA/en unknown
- 2015-06-25 AR ARP150102042A patent/AR100997A1/es not_active Application Discontinuation
- 2015-06-25 US US14/751,007 patent/US9242968B2/en active Active
- 2015-12-09 US US14/963,754 patent/US9447046B2/en active Active
-
2016
- 2016-07-26 US US15/220,118 patent/US9586902B2/en active Active
- 2016-12-18 IL IL249629A patent/IL249629A0/en unknown
- 2016-12-22 CL CL2016003301A patent/CL2016003301A1/es unknown
- 2016-12-22 SA SA516380585A patent/SA516380585B1/ar unknown
-
2017
- 2017-01-09 US US15/402,100 patent/US9815828B2/en active Active
- 2017-01-16 CO CONC2017/0000359A patent/CO2017000359A2/es unknown
- 2017-01-24 EC ECIEPI20174931A patent/ECSP17004931A/es unknown
- 2017-10-24 US US15/792,570 patent/US9994561B2/en active Active
-
2018
- 2018-05-04 US US15/971,749 patent/US10106534B2/en active Active
-
2021
- 2021-03-01 CY CY20211100169T patent/CY1123906T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210299T1 (hr) | Inhibitori histonske demetilaze | |
| PH12018501179A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
| TR201903322T4 (tr) | Kinaz inhibisyonu için heteroaril bileşikleri. | |
| MX2020005622A (es) | Compuestos de indol sustituidos con arilo y heteroarilo. | |
| PH12018502427A1 (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| MX2020005513A (es) | Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr). | |
| EA201650031A1 (ru) | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| MX386089B (es) | Compuesto heterociclico utilizado como inhibidor de fgfr. | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| EA201890165A1 (ru) | Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа | |
| HUE070489T2 (hu) | Lanifibranor deuterizált származékainak terápiás alkalmazása | |
| MX369369B (es) | Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
| NZ629037A (en) | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same | |
| JP2017523152A5 (https=) | ||
| EA201401082A1 (ru) | Фармацевтические препараты, содержащие антагонисты ccr3 | |
| EA201600636A1 (ru) | 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды | |
| EA201790847A1 (ru) | Композиции и способы лечения с применением пролекарств тизоксанида, его аналога или соли | |
| BR112016011016A8 (pt) | derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica. |